Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials

Sanofi has moved clinical trial patients out of Ukraine, as European pharma companies scramble to maintain their multiple sclerosis studies in the wake of the conflict brought on by the Russian invasion.